Novartis provides update on fingolimod Phase III trial in primary progressive MS
The safety results were consistent with the well-characterized safety profile of fingolimod in relapsing MS (RMS). PPMS is a disorder of the central nervous system (CNS) which affects
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.